Absorption, Distribution, Metabolism and Excretion (ADME) profiling is an important aspect of any drug discovery process as it investigates the four criteria that influence the drug levels and kinetics of drug exposure to the tissues ultimately influencing the performance and pharmacological activity of the compound as a drug. It is vital to carry out in vitro ADME assays to prevent a lot of time and money being spent on compounds that are toxic to humans. Drug discovery research plays an important role in identifying and producing new drugs that are targeted to the ever emergent infections suffered by man. NoAb BioDiscoveries (www.noabbiodiscoveries.com) is a contract research organization that helps pharmaceutical developers identify viable clinical candidates by providing an array of research services. To help shape and optimize the drug discovery process, NoAb BioDiscoveries has developed a range of specialized and proprietary research services that include in vivo pharmacokinetics studies, in vitro ADME assays, bioanalytical services and gene expression assays that focus on lead selection and optimization.
These assays are continuously improved upon at NoAb BioDiscoveries using innovation to produce advanced research tools that better characterize the pharmacokinetic properties of new drug candidates, optimizing the selection of viable clinical candidates. Using the advanced in vivo pharmacokinetic studies, the high throughput in vitro ADME assays and the innovative DTExâ"¢ technology for gene expression profiling, NoAb BioDiscoveries promises to facilitate your success and accelerate timelines during the drug discovery process. Ultimately, the accelerated discovery services lead to reduced costs and time for marketing a new drug and maximization of your success. This research facility offers premier drug discovery services to its clients that help them to profile compounds and select the best candidates for further pre-clinical and clinical development. The state-of-the-art facility houses advanced instrumentation such as LC-MS/MS and HPLC equipment and all services are carried out by highly trained and experienced scientists in-house, under strict guidelines.
The team of expert scientists design the best strategies and protocols for any drug discovery need and skillfully perform standard and specialized procedures according to customer specifications. The complete range of services that includes in vitro ADME assays and in vivo pharmacokinetics studies allows for the generation of reliable and accurate information in vitro as well as the proper interpretation and extrapolation of the information generated in in vivo situations. The in vitro ADME assays are high quality and highly efficient assays that produce accurate information that can be used to select and prioritize leads. The results of the assays together with preliminary toxicity evaluations assist in developing the hits from high throughput screening (HTS) into leads. The leads are then further optimized into promising drug candidates that can be developed for phase I clinical trials in humans.
In vitro ADME assays include cell permeability, plasma protein binding, cytochrome P450 subtype inhibition, metabolic stability in hepatocytes, metabolic stability in liver subcellular fractions, plasma stability and cytotoxicity assays. Gene expression profiling using DTExâ"¢ micro-array technology is also used for ADME profiling of efflux and uptake transporters, phase I and II metabolic enzymes and nuclear X receptor transcription factors. NoAb BioDiscoveries is committed to accelerating the drug discovery process, providing reliable and accurate results and using innovation to build the future of drug discovery design to satisfy you and ensure your success; make sure to visit www.noabbiodiscoveries.com for drug discovery research that embodies quality, efficiency and timeliness!
